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Abstract
Background: The identification of epitopes in proteins recognized by medically relevant antibodies is useful for the
development of peptide-based diagnostics and vaccines. In this study, epitopes in the cytoplasmic repetitive antigen
(CRA) and flagellar repetitive antigen (FRA) proteins from Trypanosoma cruzi were identified using synthetic peptide
techniques and pooled sera from Chagasic patients. The epitopes were further assayed with an ELISA assay based on
synthetic peptides.
Methods: Twenty-two overlapping synthetic peptides representing the coding sequence of the T. cruzi CRA and FRA
proteins were assessed by a Spot-synthesis array analysis using sera donated by patients with Chagas disease. Shorter
peptides were selected that represented the determined epitopes and synthesized by solid phase synthesis to evaluate
the patterns of cross-reactivities and discrimination through an ELISA-diagnostic assay.
Results: The peptide Spot-synthesis array successfully identified two IgG antigenic determinants in the CRA protein
and four in FRA. Bioinformatics suggested that the CRA antigens were unique to T. cruzi while the FRA antigen
showed similarity with sequences present within various proteins from Leishmania sp. Subsequently, shorter
peptides representing the CRA-1, CRA-2 and FRA-1 epitopes were synthesized by solid phase synthesis and assayed
by an ELISA-diagnostic assay. The CRA antigens gave a high discrimination between Chagasic, Leishmaniasis and
T. cruzi-uninfected serum. A sensitivity and specificity of 100% was calculated for CRA. While the FRA antigen showed
a slightly lower sensitivity (91.6%), its specificity was only 60%.
Conclusions: The epitopes recognized by human anti-T. cruzi antibodies have been precisely located in two biomarkers
of T. cruzi, CRA and FRA. The results from screening a panel of patient sera through an ELISA assay based on peptides
representing these epitopes strongly suggest that the sequences from CRA would be useful for the development of
diagnostic reagents that could improve upon the sensitivity and specificity of currently available diagnostic tests.
Overall, the results provide further evidence of the usefulness of identifying specific linear B-cell epitopes for improving
diagnostic tools.
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Background
Chagas disease is caused by the protozoan Trypanosoma
cruzi, which belongs to the Trypanosamatidae family [1].
Infection with T. cruzi is endemic across 18 countries of
Latin America with an estimated 16 to 18 million cases
and up to 120 million additional people are at risk [2].
During the chronic phase of the disease, diagnosis of an
infection relies on serological assays since there is a
major decline in the number of parasites circulating in
patients’ blood [3,4]. The most common techniques used
are ELISA, indirect hemagglutination (IH), indirect im-
munofluorescence (IIF), western blot and immunochro-
matography [4,5]. While these methods are usually simple
to perform and have a low cost, they also can demonstrate
low sensitivity and/or specificity, or even cross-reactions
with other pathogens, especially Leishmania spp. Cross-
reactivity is a major concern when whole or semi-purified
extracts of T. cruzi epimastigotes are used as antigens in
serological tests [5].
The antigenic determinants used as binding targets for
antibodies can be divided into two categories: linear or
nonlinear. Linear epitopes consist of amino acid residues
that are adjacent to each other in the primary sequence
while nonlinear epitopes consist of amino acid residues
that are separated in the primary structure but are
brought into proximity when the protein is in its native
form. At present, there is no simple way to identify non-
linear epitopes in the absence of three-dimensional
structural information displaying antibody-antigen com-
plexes, normally with monoclonal antibodies (mAb).
However, the identity of linear epitopes can be predicted
by computer programs that calculate various parameters
that have been discovered to be correlate with the anti-
genic nature of previously studied antigens (e.g., hydro-
philicity, flexibility and surface probability) [6]. The
methods postulate that (a) antibodies bind to linear epi-
topes by reacting with segments of 4–8 consecutive
amino acid residues and (b) these epitopes are situated
on the surface of molecules, which tend to be hydro-
philic. However, computational techniques are not yet
sufficiently sophisticated to achieve the accuracy of ex-
perimental techniques. Other methods for identifying
antibody binding sites involve: (a) proteolysis of the
antigen, (b) recombinant techniques, (c) phage display,
(d) mass spectrometry and (e) the use of synthetic pep-
tides. Fragments of antigens derived from trypsin [7] or
papain [8] digestion have been used to determine anti-
body binding targets. Numerous attempts utilizing cyano-
gen bromide cleavage products have been published
[9,10]. The use of recombinant DNA techniques for epi-
tope mapping has been reported [11], including the appli-
cation of phage display technique to map epitopes in
various proteins [12,13]. Another approach applies mod-
ern mass spectrometry techniques to locate epitopes [14].
A more robust approach has been the use of libraries of
synthetic peptides. Geysen et al. [15] published a method
for identifying linear epitopes by using overlapping syn-
thetic peptides from known sequences. Given the recent
progress in methods for the simultaneous synthesis of a
large number of peptides, it is now practical to create ar-
rays of the corresponding peptides to all possible contigu-
ous segments of a protein of interest. The peptides are
designed with sufficient overlapping regions to contain
the minimal binding sequence. Linear epitopes are then
defined by identifying the peptides that are most strongly
associated with antibodies developed against the full-sized
antigen. This methodology has been used successfully in
numerous cases [16-19].
For Chagas disease, various antigens have been used to
improve the diagnosis of Chagas disease. Among them,
repetitive proteins (RP) represent very promising targets,
as they are usually highly antigenic [4,20,21]. Two well
characterized RP’s are the cytoplasmic repetitive antigen
(CRA) and the flagellar repetitive antigen (FRA). CRA is
a 225 kDa protein composed of a 14-amino acid repeat
that is distributed in the cytoplasm of the replicating
epimastigote and amastigote forms. FRA is a 300 kDa
protein composed of a 68-aminoacid repeat that is lo-
cated at the flagellum in all stages of the T. cruzi life
cycle [4,20,22]. These proteins are highly antigenic and
induce the production of several classes of antibody in
humans [22-24]. They were first used in combination for
diagnostic test in 1992, showing good specificity and
sensitivity [25]. Other studies also indicated that, used
together, CRA and FRA could successfully serve as anti-
gens in diagnostic tests for Chagas disease [26-28].
Despite the widespread use of CRA and FRA in a
chimeric form (CF-chimera) as a clinical marker of
Chagas disease [25,28,29], little is known about the ac-
tual antigenic determinants in CRA/FRA that are in-
volved in and responsible for antibody recognition
[21,22,28,30]. Information concerning the composition
and the locations of the major epitopes CRA and FRA
should provide insight into the antigenic properties of
the protein. Furthermore, specific details on the inter-
actions between CRA and FRA with particular an-
tibodies could advance the development of novel
antigens possessing characteristics desirable for use in
diagnostic assays. Such improvements include higher
sensitivity, greater specificity and the elimination of
cross-reactions. To achieve the aim of mapping specific
epitopes in both CRA and FRA proteins, we used the
parallel overlapping synthetic peptide method of Spot-
synthesis to create a peptide library of CRA and FRA.
This library was probed with a panel of sera from pa-
tients with Chagas disease that originated from differ-
ent endemic areas of Brazil. Based on their reactivity,
epitopes were identified and their sequences used to
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develop an ELISA-peptide assay to be used on the sero-
logical diagnosis of Chagas disease.
Methods
Materials
Super Signal® West Pico and chemiluninescent substrate were
from Pierce Biotechnology (Rockford, IL, USA). Amino-
PEG500-UC540 cellulose membranes were obtained from
Intavis AG Bioanalytical Instruments (Germany). Peroxid-
ase labeled rabbit anti-human immunoglobulin and ABTS
peroxidase substrate were from KPL (Gaithersburg, MD,
USA). Sephadex® G-25 was from Boehringer-Mannheeim
(Ingelheim, Germany) and neutravidin-coated 96-well
plates from Thermo Fischer Scientific (Waltham, MA,
USA). Bovine serum albumin, 3,3′,5,5′ tetramethylbenzi-
dine (TMB), pyperidine, acetonitrile and trifluoracetic
acid and Tween 20 were obtained from Sigma-Aldrich
Corp. (St. Louis, MO, USA) and Centricon 10 filters
from Amicon (CA, U.S.A.). CDP-Star® Substrate was from
Applied Biosystems (Grand Island, NY, USA). The
biotin-X-NHS labeling Kit, horseradish peroxidase (HRP)
conjugated sheep anti-human IgG, amino acids for pep-
tide synthesis, sequence reagents and all other chemical
reagents were from Calbiochem-Merck (Darmstadt,
Germany).
Human sera
Sera from patients chronically infected with T. cruzi
(n = 31) and L. brasiliensis (n = 14) were obtained from
the Parasitic Diseases Laboratory (IOC/FIOCRUZ) and
Gonçalo Moniz Research Center/FIOCRUZ-Bahia, re-
spectively. The Chagasic patients were from Vergim da
Lapa (State of Minas Gerais) and with Leishmaniasis from
the state of Bahia. Their diagnosis was confirmed both
clinically (through the clinical signs and symptoms) and
serologically (IFI and ELISA) before inclusion in the study.
Sera from unaffected donors (negative control, n = 11)
was obtained from the blood bank of Rio de Janeiro
(HEMORIO).
Synthesis of the cellulose-membrane-bound peptide array
The entire sequences of both CRA and FRA were cov-
ered by the synthesis of 10 and 12 peptides, respectively,
each with 14 amino acids and offset from the previous
by nine amino acids. The peptides were automatically
prepared onto Amino-PEG500-UC540 cellulose mem-
branes according to standard SPOT synthesis protocols
[31] using an Auto-Spot Robot ASP-222 (Intavis Bioanalytical
Instruments AG, Köln, Germany). Coupling reactions
were followed by acetylation with acetic anhydride (4%, v/v)
in N, N-dimethyformamide to render peptides unreactive
during the subsequent steps. After acetylation, Fmoc pro-
tective groups were removed by the addition of piperidine
to render nascent peptides reactive. Amino acids were
added sequentially by this same process of coupling,
blocking and deprotection until the desired peptide was
generated. After addition of the last amino acid in the
peptide, the amino acid side chains were deprotected
using a solution of dichloromethane–trifluoracetic acid–
triisobutylsilane (1:1:0.05, v/v/v) and washed with metha-
nol. Membranes containing the library of synthetic pep-
tides were either probed immediately or stored at −20°C
until needed. Positive and negative controls were included
in each membrane. The positive control consisted of a
spot with the peptide, IHLVNNESSEVIVHK, from Clos-
tridium tetani precursor and the negative control was a
spot without peptide.
Screening of SPOT membranes
SPOT membranes were washed with TBS (50 mM Tris-
buffer saline, pH 7.0) and then blocked with TBS-CT
(Tris-buffer saline, 3% casein, 0.1% Tween 20, pH 7.0) at
room temperature under agitation or overnight at 4°C.
After extensive washing with TBS-T (Tris-buffer saline,
0.1% Tween 20, pH 7.0), membranes containing the pep-
tide libraries were incubated for 2 h with sera pool from
six different Chagasic patients (1:250) in TBS-CT and
then washed again with TBS-T. Next, membranes were
incubated with alkaline phosphatase labeled rabbit anti-
human IgG (1:5000 in TBS-CT) for 1 h, washed with
TBS-T and a final wash in CBS (50 mM citrate-buffer sa-
line, pH 7.0). Chemiluminenscente CDP-Star® Substrate
(0.25 mM) with Nitro-Block-II™ Enhancer (Applied Bio-
systems, USA) was added to complete the reaction.
Scanning and measurement of spot signal intensities
The measurement of spot signal intensities were per-
formed as described previously [32]. Briefly, the chemi-
luminescent signals were measured on a MF-ChemiBis
3.2 (DNR Bio-Imaging Systems, Israel) and a digital
image file generated with a resolution of 5 MP. Signal
intensities were quantified with TotalLab Software (Non-
linear Dynamics, USA) using algorithms that compared
the intensity between background, spot area and negative
control to define the empirical probability that the spot
signal intensity was distinct from background signals. The
spot with the strongest reactivity on the membrane was
defined as an intensity of 100% and all other intensities
were expressed as values relative to this intensity.
Peptide synthesis
Peptides consisting of the sequences of the identified
and selected epitopes from the screening of the CRA
and FRA peptide libraries were synthesized by solid phase
using the F-moc strategy and an automatic synthesizer
(PSS-8-Shimadzu, Japan). Epitope sequences (CRA-1 =
AAKQKAAEAAAKQKAAEC; CRA-2 = AAKQRAAEA
AAKQR AAEC) were each linked in tandem with the
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insertion of three Ala and were extended by the addition
of extra alanine residues on the N- and Cys to the C-
terminus to improve presentation of antigens to anti-
bodies and bind to neutravidin during diagnostic tests
after biotin labeling. All fluorenylmethoxy carbonyl
amino acid derivatives were used to protect the a-amino
group and purchased from Novabiochem (San Diego,
CA, USA). To protect the side chain, triphenylmethyl
was used for Gln and Asn, t-butyl for Thr, Glu, Ser and
Asp, t-butyloxycarbonyl for Lys, and 2,2,5,7,8-penta-
methylchroman-6-sulphonyl for Arg.
Cleavage of the peptide from the resin was achieved by
treatment with a mixture of trifluoroacetic acid: thioani-
sole: ethane dithiol: water (volume ratios 80:5:2.5:5) at
room temperature for 12 h. After filtration and washing of
the resin with trifluoroacetic acid, a gentle stream of nitro-
gen was used to remove excess trifluoroacetic acid. The
crude peptide was precipitate at −20°C with diethyl ether
and then centrifuged at 3000 g for 10 min at 10°C. The
synthetic peptide was purified by high performance liquid
chromatography (HPLC) using a reverse phase column
(Vydac C18). The purified peptides were characterized by
amino acid analysis and electronspray ionization MS at
the National Institute of Quality Control on Health
(INCQS) of FIOCRUZ, Rio de Janeiro, Brazil.
Peptide biotinylation
Peptides (CRA-1 = AAKQKAAEAAAKQKAAEC; CRA-
2 = AAKQRAAEAAAKQRA AEC and FRA-4 = ADRAF
LDQKPERVPC) were labeled with biotin using the Biotin-
X-NHS Kit, which allowed attachment to solid supports
through association with immobilized neutravidin, as pre-
viously described [33]. Briefly, a solution of biotin-NHS
(40 μg/μL) prepared in 0.1 M DMF was added to each
peptide (10 μg/μL) dissolved in Na2HCO3/Na2CO3 to give
a volume ratio of 1:4 in the final solution. The peptides
were incubated at 25°C for 2 h with stirring followed by
purification on a Sephadex® G-25 column using a flow rate
of 1 ml/min. Collected biotin-labeled peptide was ly-
ophilized and stored at 4°C until use. The labeling effi-
ciency was determined according to the protocol of the
manufacturer.
Determination of the peptide concentration
The concentration of the peptides was estimated using
the ExPASy ProtParam tool at 205 nm using a molar ex-
tinction coefficient (http://www.basic.northwestern.edu/
biotools/proteincalc.html) previously defined. Alterna-
tively the concentration was determined by an auto-
matic amino acid analyzer (Shimadzu, Kyoto, Japan).
Molecular modeling
3D structure data was not available for either protein.
To obtain a theoretical model, the primary sequences of
CRA (access code Q26907) and FRA (access code Q26921)
of T. cruzi were accessed nine times before submission to
I-TASSER server (http://zhanglab.ccmb.med.umich.edu/I-
TASSER/) [34,35], which automatically built a predicted
model. Visualization was performed using Visual Molecular
Dynamic (VMD) 1.9 [36]. Models show the correct
topology based on TM-score values greater than 0.50,
which is a reasonable quality c-score and within accepted
limits, and demonstrated greater than 90% confidence for
the prediction of the FRA model (c-score = −1,57) and
slightly lower for the CRA model (c-score = −1,49).
ELISA
ELISA-peptide assays were performed as described pre-
viously [37] using neutravidin coated plates. Briefly,
neutravidin-coated 96-well plates were incubated with
2 mg/mL of each biotin-labeled peptide (100 μL/well)
for 2 h at room temperature. After three washes with a
wash solution (TBS pH 7.2, containing 0.05% of Tween
20 and 0.1% skimmed milk), diluted human sera (1:50)
was added and incubated for 30 minutes at room
temperature. Following three washes in wash solution,
the sheep anti-human IgG antibody coupled with horse-
radish peroxidase (HRP) was added at a dilution of
1:14,000 in wash solution and incubated for 30 minutes
at room temperature. After three washes, 100 μL of
ABTS peroxidase substrate was added to each well and
the optical density (OD) was measured at 405 nm fol-
lowing a 30 minute incubation.
Analysis of the experimental data
The results of ELISA were analyzed through the Receiving
Operator Characteristic (ROC) curves, which are equiva-
lent to Wilcoxon statistics [38,39]. Cut-off values were de-
termined using the ROC curve analysis [40]. All statistical
analyses were performed with SigmaPlot 10.0 software
(Systat Software Inc., Chicago, USA).
Results
Linear epitope mapping
Linear epitopes often contain between two and six
amino acids that are critical for recognition by an anti-
body [41,42]. Together with advances in automated pep-
tide synthesis make, it is feasible to generate peptide
arrays that span the entire amino acid sequence of a pro-
tein. Considering the potential for the T. cruzi RP’s CRA
and FRA to act as antigens for diagnosing infections,
two libraries of peptides were designed to cover the
amino acid sequence for each. By screening each library
with a pool of serum from Chagas patients (n = 6), each
of the antigenic epitopes could be identified for further
analysis.
Ten peptides were sufficient to represent the amino
acid sequence of CRA and were synthesized in place
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onto membranes. This peptide array was screened ini-
tially with sera pooled from six patients with Chagas
disease. The recognition and binding by anti-CRA anti-
bodies was detected by chemiluminescence. A represen-
tative image is shown in Figure 1A demonstrating that
each peptide was reactive to some extent. A plot of the
quantified signal intensities clearly identified the epi-
topes with the greatest reactivity (Figure 1B). The profile
of antigenicity was not dependent on which sera were
included in the pools as different pools of sera resulted
in the same profiles suggesting that the reactivity was in-
dependent of the possible variability in the relative abun-
dance of antibody clones that were reactive with each
particular epitope in the proteins (data not shown).
With the sequences that constitute each peptide
(Figure 1C), the epitopes were characterized by a theoretical
model of their structure. The three major antigenic
regions identified had very similar sequences with the only
difference between them being the amino acid in the
third position; a lysine residue in CRA-1 (7KQKAAE15)
and an arginine in CRA-2 & CRA-5 (KQRAAE). As a
consequence, all of the 9 amino acid sequences were
modeled with very similar structures composed of a ran-
dom coil (CRA-1) or as a turn (CRA-2 &-5) as predicted
by the I-TASSER server. Their locations, according to
the predicted model, also supported their potential to
interact with antibodies in solution (in red, Figure 1D).
The first peptide, CRA-1, was located at the C-terminus
and appeared to be exposed to the solvent. The second
and third peptides, CRA-2 and CRA-5, appeared to form
a loop on the surface of the protein. The peptide A5 was
situated at the end of ß-sheets, which could explain its
strong signal.
Equivalent experiments were performed to identify
linear B-cell epitopes in FRA using twelve peptides. In
Figure 2A, a representative image of a membrane con-
taining the peptide array demonstrated greater variabil-
ity in the reactivity against sera from Chagas patients
than the peptides for CRA. The measured intensities
plotted in Figure 2B suggested four potential epitopes
from the sequences of the peptides presented in Panel
C. Three of them (FRA-1, FRA-2 and FRA-3) consisted
Figure 1 Linear epitope mapping of CRA with human patient sera. Peptides consisting of 14 amino acid residues with an overlap of 9
residues between peptides were tested for reactivity against a pool of sera from six Chagasic patients. (A) Image of a representative membrane
revealed by chemiluminescence after immunoblotting. (B) Measured signal intensity of the spots from membrane in Panel A. (C) Peptide
sequences synthesized and the position of their spots. (D) Molecular modeling of CRA protein predicted by I-Tasser server. The visualization of
the proteins was executed as a “new cartoon” representation with the quality set at the maximum value (50). The red segments are overlapping
epitopes with the greatest signals contrasted against the rest of repeated structure in blue color.
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of sequences with only four amino acids (5RRQL8,
16NAKE19 and 26SMNA29). While their positions in
the predicted model suggested that they were located at
the surface of the proteins (Figure 2D), they were con-
sidered too small for use in the intended application as
antigens for ELISA assays. However, the forth epitope
(FRA-4) consisted of 14 amino acids (41ADRAFLDQ-
PERVP54) that was predicted to form a random coil
structure by the I-TASSER server. Its high level of re-
activity suggested that it was a promising candidate for
use as an antigen in ELISA for detecting antibodies as-
sociated with T. cruzi infections.
All potential candidates are listed in Table 1. A search
was performed to compare these sequences against pro-
tein databases to predict their cross-reactivity in diag-
nostic assays. In Table 2, the proteins identified by the
analysis are listed by name and accession number along
with their source and percent identity. For CRA-1 and
CRA-2, multiple proteins demonstrated identical se-
quences, but each also originated from T. cruzi suggest-
ing the feasibility to use these epitopes as T. cruzi
specific antigens. The same was not true for the epitope
discovered in FRA. Although very reactive with sera
from Chagasic patients, this sequence was not specific
to T. cruzi based on the discovery of similar sequences
contained in proteins from L. braziliensis and L. infantum.
ELISA-peptide assay
The impetus for identifying the linear B-cell epitopes in
CRA and FRA was to improve on their use as antigens
for diagnostic ELISA assays. To verify their utility, peptides
Figure 2 Linear epitope mapping of FRA with human patient sera. Peptides 14 amino acid residues long with an overlap of 9 residues
between peptides were tested for reactivity against a pool of sera from six Chagasic patients. (A) Image of a representative membrane revealed
by chemiluminescence after immunoblotting. (B) Measured signal intensity of the spots produced from the image in Panel A. (C) Sequences of
the peptides synthesized and their positions on the membrane. (D) Molecular model of the FRA protein as predicted by I-Tasser server.
Visualization of proteins was generated as a “new cartoon” representation with the quality of visualization was set at the maximum value of 50.
The red segments display the overlapping epitopes with highest signals amongst the rest of the repeated structure in blue.
Table 1 Linear epitopes identified in CRA and FRA
proteins of T. cruzi and their amino acid positions
Protein Epitope sequence Position
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were synthesized from sequences derived from the potential
CRA and FRA epitopes, the two major antigenic regions
in CRA (CRA-1 and CRA-2) and the one in FRA (FRA-4),
by solid phase synthesis using the F-moc strategy. Since
both epitopes identified in CRA were 6-9-residues long,
the potential for antigenic presentation in a diagnostic test
was improved by synthesizing both with alanine residues
as spacers (CRA-1 = AAKQKAAEAAAKQKAAEC; CRA-
2 = AAKQRAAEAAAKQRAAEC). The FRA-4 epitope
was already composed of 14 residues, so its sequence was
not modified for synthesis (FRA-4 = ADRAFLDQK-
PERVPC). After synthesis, the peptides were conjugated
with biotin at the C-terminus to allow easy attachment
to ELISA plates through association with immobilized
neutravidin.
To verify the diagnostic performance of the peptides,
sera from thirty-one Chagasic patients (positive by indir-
ect fluorescence), sera from fourteen Leishmaniasis pa-
tients and twelve healthy donors (negative) were tested
on an ELISA-peptide based assay. The results are shown
in Figure 3 and were considered significant (p < 0,001).
Using the ROC curve analysis, the best values were associ-
ated with the CRA-1 and CRA-2 peptides and considered
by a scale value as good test. Both of the CRA antigens
demonstrated 100% sensitivity and specificity. The FRA
antigen, however, presented a high cross reactivity with
Leishmaniasis patient’s sera and by the ROC curve ana-
lysis represented a failed test by exhibiting a specificity of
only 60% even with a sensitivity of 91.6%.
Discussion
The development of improved assays for detecting T.
cruzi infections, which can lead to Chagas disease, de-
pends on the availability of specific, high-affinity anti-
gens. In particular, useful antigens include those that are
bound at equimolar levels to reactive antibodies present
in serum and those that distinguish between antibodies
derived against similar pathogens. The identification of
antigens as strongly reactive linear epitopes and their
characterization would permit their localization in pro-
tein models, definition of their biophysical properties
and analysis of their binding properties with regards to
antibody class, capacity, specificity and selectivity. Despite
the determination of the RPs CRA and FRA as antigens
for diagnostic purposes through various immunological
studies [24,27,29,30,43], there are no published data about
Table 2 Specificity of the antigenic regions present in CRA and FRA sequences that were identified by the Spot-synthesis




Protein name Organism Identity
(%)
CRA-1 (KQKAAEATK)
Q9NJH4 Antigen JL8 T. cruzi 100
Q4DV01 R27-2 protein, putative T. cruzi 100
Q4DN44 Putative uncharacterized protein T. cruzi 100
Q26947 R27-2 protein T. cruzi 100
E7LGS7 Putative uncharacterized protein T. cruzi 100
B9V414 Antigen T. cruzi 100
CRA-2 (KQRAAEATK)
Q4DV01 R27-2 protein, putative T. cruzi 100
Q4DN44 Putative uncharacterized protein T. cruzi 100
Q26947 R27-2 protein T. cruzi 100
E7LGS7 Putative uncharacterized protein T. cruzi 100
B9V414 Antigen T. cruzi 100
FRA-4 (ADRAFLDQPERVP)
Q04946 Cytoskeleton associated protein T. cruzi 92
Q4CS87 Calpain cysteine peptidase, putative T. cruzi 92
Q4CPQ6 Calpain cysteine peptidase, putative T. cruzi 92
Q26898 Antigen DNA (tandem repeat sequence) T. cruzi 92
E7LGE0 Calpain cysteine peptidase, putative T. cruzi 92
A4HFX3 Putative calpain-like cysteine peptidase L. braziliensis 90
E9AHC1 Putative cysteine peptidase L. infantum 76
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the number and composition of their epitopes at the
amino acid level.
In our study, the mapping of linear epitope through
parallel synthesis of overlapping peptides was chosen
based on the volume of useful information provided and
the high spatial resolution of the technique. Screening of
the potential linear epitopes with sera from infected pa-
tients indicated the presence of two major antigenic and
apparently highly specific epitopes in CRA when evalu-
ated against the sera of Leishmanisis patients. The two
epitopes had very similar sequences in comparison to
each other. This result was similar to that of Pereira
et al. [44], which demonstrated that the LamB fusion
protein, a 14-residue peptide, was highly antigenic in
mice and contained an immunodominant B cell epitope.
Here, we were able to restrict the antigenic sequence to
9 residues, which is more easily obtained from solid-
phase chemical synthesis. For FRA, the data demon-
strated, for the first time that its recognition as an
antigen was due to the presence of three small and one
major antigenic region. Although the longest one con-
sisted of 14 residues and was very reactive, its sequence
also demonstrated a high similarity to Leishmania sp.
proteins through a database search of Uniprot submis-
sions. This high degree of similarity could explain its
tendency to cross react with antibodies from patients in-
fected with Leishmania.
After analyzing several antigen-antibody structural
complexes, Rubinstein et al. [45] verified that B-cell epi-
topes are usually defined as regions with charged or
polar residues and have hydrophilic characteristics with
an undefined secondary structures, principally random
coils and turns. The sequences mapped in CRA con-
formed to this characterization and were predicted to be
very hydrophilic with a positive charge at neutral pH. In
fact, the single amino acid substitution of arginine for
lysine, defined between two epitopes in CRA, did not
change any of the physical-chemical parameters. In
addition, molecular modeling indicated that these epi-
topes were present in regions with undefined 3D struc-
tures as either a turn or a random coil. In contrast, the
major FRA-4 epitope was calculated to have a slight
negative charged, but also had a highly hydrophilic na-
ture. The structural prediction indicated a random coil
conformation. These results show that, in all three cases,
the absence of a rigid 3-D organization may have contrib-
uted to the antigenicity of these sequences by increasing
their exposure and availability to antibody binding.
Both CRA and FRA proteins have already been used
as antigens in a variety of studies on the diagnosis of
Chagas disease. Krieger et al. [25] published the first ac-
count to show that the sensitivity and specificity of ELISAs
could approach 100% with a mixture of the recombinant
forms of CRA and FRA as antigens. It also demonstrated
Figure 3 Capacity of the (CRA-1, CRA-2 and FRA-4) synthetic peptides to discriminate between serums infected by T. cruzi and
Leishmania in a ELISA. Chagasic (n = 31) and Leishmaniasis (n = 14) patient sera, and healthy individual sera (n = 11) were diluted 1:50 and
evaluated in triplicates against the peptide sequences CRA-1 (AAKQKAAEAAAKQKAAEAC-biot), CRA-2 (AAKQRAAEAAAKQRAAEC-biot) and FRA-4
(ADRAFLDQKPERVPC-biot). All tests were considered significant (p < 0,001) and the cut-off values of 0.226 for CRA-1, 0.199 for CRA-2 and 0.254 for
FRA-1 were calculated. Each point of the graphic represents the media of two experiments.
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that their diagnostic performance was improved when
both proteins were used together rather than individually.
A similar observation was made [28], using recombinant
CRA and FRA on a microsphere-based serological test.
However, when using a mixture of both recombinant
CRA and FRA in ELISA for blood bank screening,
Carvalho et al. [27] observed a decrease in the sensitivity
of the test. This could be attributed to the observation
that, when using whole proteins, a variety of epitopes are
actually presented that could lead to some cross-reactions.
An alternative to circumvent this issue is to develop a
diagnostic test based on peptides as antigens, either indi-
vidually, in mixtures or through multi-epitope structures.
Some ELISA tests based on this approach have been
tested for Chagas disease diagnosis. The results showed
sensitivity in the range of 96.8 to 100% and specificity
around 99% [4].
In this work, we were able to successfully use synthetic
peptides in an ELISA-based diagnostic test for Chagas
disease. The sequences of the peptides were defined by
the reactivity of pooled sera from Chagas patients
against a library of peptides designed to span coding re-
gion of CRA and FRA. To determine the best cut-off
values for each test, a ROC curve analysis was chosen
for the analysis because it permitted the researchers to
fit test values and to achieve the best parameters accord-
ing to defined objectives (for example, better sensitivity,
better specificity or the best of both, simultaneously).
With this approach, ELISA-based diagnostic tests that
used either of CRA antigens achieved 100% sensibility
and specificity, while FRA antigen showed a lower sensi-
tivity of 91.5% and a specificity of 60%. This balance was
pursued in order to overcome the fact that similar se-
quences could also be found in Leishmania sp. proteins
(on a database search at Uniprot), thus avoiding cross-
reactions on the test.
We expect that the localization and characterization of
the association targets of anti-CRA/FRA antibodies will
aid in further structural insights for development of more
sensitive and specific assays for Chagas disease.
Conclusion
The molecular characterization of epitopes on antigens
exposes potential benefits, both from an applied and a
basic research perspective. Native or recombinant anti-
gens are powerful reagents for serological tests because
they contain a large spectrum of epitopes that covert the
multitude of variations presented by individual responses.
However, there is always a balance between the inclusion
of diagnostically relevant epitopes contained in the anti-
gens versus cross-reactive epitopes. Our work focuses on
identifying linear sequences within antigens recognized by
antibodies in patient sera to precisely map each epitope
and allows characterization of their performance as
diagnostic tools. In this study, we have located epitopes in
the CRA and FRA proteins from T. cruzi. The epitopes
from CRA demonstrated high specificity, while the largest
epitope from FRA displayed extensive cross-reactivity.
Their utility in diagnostic kits was tested by a peptide-
based ELISA and the CRA epitopes will be useful for
refining diagnostic reagents with a design towards higher
performance displaying greater sensitivity and specificity.
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